REMS Need To Be More Easily Modified, Attorney Says; Prior Approval Supplements Too Cumbersome
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA could facilitate improvements to Risk Evaluation and Mitigation Strategies by giving companies some discretion to modify REMS elements, according to Hogan and Hartson partner Meredith Manning